Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies

Identification of Responder and Disease Activity Thresholds for the Psoriatic Arthritis Impact of Disease-12 (PsAID-12) Questionnaire Using Pooled Data from Two Phase 3 Trials of Bimekizumab in Patients with Psoriatic Arthritis

Achievement of Low Disease Activity Over 52 Weeks in Patients with Active Axial Spondyloarthritis on Bimekizumab Treatment: Results from the Phase 3 Studies BE MOBILE 1 and BE MOBILE 2

Bimekizumab Treatment Resulted in Clinically Meaningful Improvements in the Psoriatic Arthritis Impact of Disease-12 (PsAID-12) Scores Using Pooled Results from Two Phase 3 Trials in Patients with Psoriatic Arthritis

Resolution of Enthesitis and Peripheral Arthritis with Bimekizumab in Patients with Axial Spondyloarthritis: Week 52 Results from the BE MOBILE 1 and BE MOBILE 2 Phase 3 Studies

An Exploratory Analysis of the Potential Disconnect Between Objective Inflammatory Response and Clinical Response Following Certolizumab Pegol Treatment in Patients with Active Axial Spondyloarthritis

Low Uveitis Rates in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Pooled Results from Phase 2b/3 Trials

Patients with Psoriatic Arthritis at Biologic Therapy Switch: The CorEvitas Psoriasis Registry

Comparison of Established and New, Preliminarily Proposed ASAS Cut-Offs for Inflammatory MRI Lesions in the Sacroiliac Joints in Axial Spondyloarthritis and Implications for Recruitment in Clinical Studies

Performance Analysis of a Deep Learning Algorithm to Detect Positive SIJ MRI According to the ASAS Definition in axSpA Patients

Bimekizumab Efficacy and Safety in Biologic DMARD-Naïve Patients with Psoriatic Arthritis was Consistent With or Without Methotrexate: 52-Week Results from the Phase 3 Active Reference Study BE OPTIMAL

Sustained Efficacy and Safety of Bimekizumab in Patients with Active Psoriatic Arthritis and Prior Inadequate Response to Tumour Necrosis Factor Inhibitors: Results from the Phase 3 BE COMPLETE Study and its Open-Label Extension up to 1 Year

Bimekizumab Reduced MRI Inflammatory Lesions in Patients with Axial Spondyloarthritis: Week 52 Results from the BE MOBILE 1 and 2 Phase 3 Studies

Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naïve Patients with Psoriatic Arthritis Who Were Responders at Week 16: Results from BE OPTIMAL, a Phase 3, Active Reference Study

Bimekizumab Maintained Stringent Clinical Responses Through Week 52 in Patients with Axial Spondyloarthritis: Results from the Phase 3 Studies BE MOBILE 1 and BE MOBILE 2

Bimekizumab Maintained Improvements in Efficacy Endpoints and Had a Consistent Safety Profile Through 52 Weeks in Patients with Axial Spondyloarthritis: Results from Two Parallel Phase 3 Studies